

Media Release

Mumbai, 9th May 2017

RECORD ANNUAL CONSOLIDATED NET PROFIT OF ₹ 709.65 MILLION, UP 37%

RECORD ANNUAL CONSOLIDATED EBIDTA OF ₹ 1183.70 MILLION, UP 27%

RECORD ANNUAL CONSOLIDATED Revenue OF ₹ 3068.06 MILLION, UP 27%

QUARTERLY CONSOLIDATED NET PROFIT OF ₹ 189.50 MILLION, UP 23%

QUARTERLY CONSOLIDATED EBIDTA OF ₹ 331.70 MILLION, UP 24%

QUARTERLY CONSOLIDATED Revenue OF ₹ 876.71 MILLION, UP 23%

Thyrocare Technologies Limited (the “company”) today reported its financial performance for the quarter/ year ended March 31, 2017. Thyrocare Technologies Limited has continued to grow ahead compared to the Industry standards and posted encouraging growth of 28% in pathology business.

The preventive care brand ‘Aarogyam’ coupled with the other initiatives in the form of regional processing laboratories, BTECHs, direct sales associates, corporate/ institutional business, online clients, direct bookings, etc. has significantly contributed to the growth during the financial year. The revenue from B2C segment has also contributed to the growth in the revenue. The preventive care brand ‘Aarogyam’ alone constitutes more than 52% of the total revenue from pathology business and Thyrocare Technologies Limited emerged as the premium and cost effective preventive care healthcare solution provider in the segment.

Media Release

Thyrocare Technologies Limited has widespread business across the country with touch points scattered pan India. During the financial year, the company has generated around 29% of total revenue from West, 26% from South, 21% from North and around 16% from East region of the country. The company has performed during the year 7.65 crore investigations on 1.43 crore samples.

The total cash generated from operations during the financial year was Rs. 1299.10 million, higher by 30% over the previous financial year. The company has declared and paid interim dividend of Rs. 5 per equity share (50% on the face value of Rs. 10/- each) for the financial year 2016-2017 and further recommended for final dividend of Rs 5/- (Rupees Five only) per equity share of the face value of Rs 10 each for the financial year ended March 31, 2017. The total dividend for the year including the final dividend (subject to the approval of the shareholders at the ensuing Annual General Meeting) will be Rs 10/- (Rupees Ten only) per equity share.

Nuclear Healthcare Limited, the wholly owned subsidiary of Thyrocare Technologies Limited, also expanded its presence in Surat and Vadodra during the current financial year. The subsidiary is in the process of setting up PETCT in Raipur, Nashik, Mumbai, Jaipur and other parts of the country.

The highlights of the audited financial results as compared to the previous year are :

CONSOLIDATED FINANCIAL PERFORMANCE

(₹ in million)	3 months ended March 31, 2017 Audited	3 months ended December 31, 2016 Unaudited	3 months ended March 31, 2016 Unaudited	% change w.r.t. previous quarter	% change w.r.t. previous financial year quarter	Year ended March 31, 2017 Audited	Previous Year ended March 31, 2016 Audited	% change w.r.t. previous financial year
Revenue from operations	876.71	710.58	650.55	23%	35%	3,068.06	2,409.65	27%
EBTDA	331.70	267.56	245.85	24%	35%	1,183.70	934.97	27%
Profit after tax	189.50	153.79	139.36	23%	36%	709.65	518.01	37%
Earnings Per Share (of Rs. 10/- each) (not annualised):								
Basic	3.53	2.86	2.71	23%	30%	13.21	10.06	31%
Diluted	3.52	2.86	2.70	23%	30%	13.19	10.06	31%

Media Release

STANDALONE FINANCIAL PERFORMANCE

(₹ in million)	3 months ended March 31, 2017 Audited	3 months ended December 31, 2016 Unaudited	3 months ended March 31, 2016 Unaudited	% change w.r.t. previous quarter	% change w.r.t. previous financial year quarter	Year ended March 31, 2017 Audited	Previous Year ended March 31, 2016 Audited	% change w.r.t. previous financial year
Revenue from operations	828.74	700.85	642.76	18%	29%	3,000.59	2,351.35	28%
EBTDA	321.57	267.04	248.36	20%	29%	1,169.08	946.07	24%
Profit after tax	203.04	169.00	154.41	20%	31%	748.46	587.55	27%
Earnings Per Share (of Rs. 10/- each) (not annualised):								
Basic	3.78	3.15	3.00	20%	26%	13.93	11.42	22%
Diluted	3.77	3.14	3.00	20%	26%	13.91	11.41	22%

DISCLAIMER

This media release is for information purposes only and it contains general background information about the company's activities. The company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, information or events, or otherwise. This media release comprises information given in summary form and does not purport to be complete. This media release should not be considered as a recommendation to any investor to purchase the equity shares of the company. This media release includes statements that are, or may be deemed to be, "forward-looking statements". By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the company, its future financial condition and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the company will be achieved. The past performance is not indicative of future results.

Registered Office :

D/37-1, TTC MIDC, Turbhe,

Navi Mumbai – 400703.

CIN : U85110MH2000PLC123882

Thyrocare Technologies Limited

[Stock Code NSE/ BSE - THYROCARE]

Media Release